Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

Chugai Pharmaceutical Co., Ltd. (CHGCY)

29.44
+0.50
+(1.73%)
At close: 3:58:56 PM EDT
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,170,611,000
1,170,611,000
1,111,367,000
1,259,726,000
999,758,000
Cost of Revenue
339,409,000
339,409,000
413,306,000
476,251,000
338,147,000
Gross Profit
831,201,000
831,201,000
698,061,000
783,475,000
661,612,000
Operating Expense
289,199,000
289,199,000
258,887,000
250,167,000
239,715,000
Operating Income
542,002,000
542,002,000
439,174,000
533,308,000
421,897,000
Net Non Operating Interest Income Expense
1,032,000
1,032,000
4,647,000
-9,000
28,000
Pretax Income
543,034,000
543,034,000
443,821,000
531,166,000
419,385,000
Tax Provision
155,717,000
155,717,000
118,349,000
156,737,000
116,390,000
Net Income Common Stockholders
387,317,000
387,317,000
325,472,000
374,429,000
302,995,000
Diluted NI Available to Com Stockholders
387,317,000
387,317,000
325,472,000
374,429,000
302,995,000
Basic EPS
117.69
117.69
98.92
113.82
92.14
Diluted EPS
117.68
117.68
98.90
113.78
92.08
Basic Average Shares
3,290,892.03
3,290,892.03
3,290,417.63
3,290,417.63
3,288,241.36
Diluted Average Shares
3,291,274.29
3,291,274.29
3,290,997.97
3,290,671
3,290,383.88
Total Operating Income as Reported
542,002,000
542,002,000
439,174,000
533,309,000
421,897,000
Total Expenses
628,608,000
628,608,000
672,193,000
726,418,000
577,862,000
Net Income from Continuing & Discontinued Operation
387,317,000
387,317,000
325,472,000
374,429,000
302,995,000
Normalized Income
387,317,000
387,317,000
325,472,000
374,429,000
302,995,000
Interest Income
5,000
5,000
--
--
--
Interest Expense
--
--
27,000
61,000
48,000
Net Interest Income
1,032,000
1,032,000
4,647,000
-9,000
28,000
EBIT
542,002,000
542,002,000
443,848,000
531,227,000
419,433,000
EBITDA
542,002,000
542,002,000
443,848,000
531,227,000
419,433,000
Reconciled Cost of Revenue
339,409,000
339,409,000
413,306,000
476,251,000
338,147,000
Net Income from Continuing Operation Net Minority Interest
387,317,000
387,317,000
325,472,000
374,429,000
302,995,000
Normalized EBITDA
542,002,000
542,002,000
443,848,000
531,227,000
419,433,000
Tax Rate for Calcs
0
0
0
0
0
12/31/2021 - 8/3/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DSNKY Daiichi Sankyo Company, Limited
23.50
+1.34%
 
AMRN Amarin Corporation plc
11.18
+7.92%
 
MIRA MIRA Pharmaceuticals, Inc.
0.9942
+7.95%
 
AZN AstraZeneca PLC
69.55
+1.52%
 
LLY Eli Lilly and Company
859.73
+3.65%
 
NVS Novartis AG
111.17
+0.94%
 
SNY Sanofi
53.54
+0.98%
 
NVO Novo Nordisk A/S
62.63
+2.17%
 
GILD Gilead Sciences, Inc.
106.15
-0.22%
 
AZN.ST AstraZeneca PLC
1,337.00
+0.94%